Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ImmunoCode

Financiado

Cerrado

Digital Single Cell Immunology Decoding Cellular Interactions for Improved Immu...

Digital Single Cell Immunology Decoding Cellular Interactions for Improved Immunotherapy Successful immunotherapy against cancer is the result of a multitude of cellular interactions within the immune system. It is highly exciting how vaccination with small numbers of human plasmacytoid dendritic cells (pDCs) can indu... ver más

30/06/2024

TU/e

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

TECHNISCHE UNIVERSITEIT EINDHOVEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-06-30

ERC-2018-STG: ERC Starting Grant

I+D

Cerrada hace 7 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

TU/e

1.81M€ | Lider

INDENOVA

313.55K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2020-116393RB-I00 NUEVA GENERACION DE INMUNOTERAPIAS CONTRA CANCER BASADAS EN... 257K€ Cerrado

CAR-TIME Drivers and Brakes of CAR T Cell Efficacy Determined by the... 1M€ Cerrado

cDCFun Conventional Dendritic Cells – Ecology, Diversity, and Funct... 2M€ Cerrado

KineTic New Reagents for Quantifying the Routing and Kinetics of T c... 2M€ Cerrado

PID2020-118529RB-I00 EXPLOTANDO LOS DETERMINANTES MOLECULARES DE LA RESPUESTA T A... 218K€ Cerrado

DENDRITIC CELLS Identification and targeting of metabolic pathways in dendri... 75K€ Cerrado

Duración del proyecto: 68 meses Fecha Inicio: 2018-10-23
Fecha Fin: 2024-06-30

Líder del proyecto

TECHNISCHE UNIVERSITEIT EINDHOVEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Successful immunotherapy against cancer is the result of a multitude of cellular interactions within the immune system. It is highly exciting how vaccination with small numbers of human plasmacytoid dendritic cells (pDCs) can induce anti-tumour immunity in metastatic cancer patients. Remarkably, how pDCs, as an extremely rare subset of cells, can act as Swiss army knives to regulate the tight balance between tolerance and immunity: i.e. secrete massive amounts of type I IFNs, prime T cells and exert cytotoxic effector functions, is still elusive. Do pDCs possess all functions or comprises the population distinct functional subsets all with their specialized roles. I will unravel which pDC is superior in inducing cytotoxic T cells (CTLs) for augmented cancer immunity. Despite advances in single cell technologies, understanding the role of heterogeneity in immune cell populations, remains poorly understood. In ImmunoCode, I will develop a novel and ambitious single cell technology platform, wherein innovative microfluidic approaches and single cell transcriptomics allow 1) functional analysis of single (pairs of) immune cells and 2) design of minimal environments under the omission of external factors that could influence cellular behaviour. This approach will provide me with the unique opportunity to unravel pDC function and plasticity. Although in this ERC proposal I will focus on understanding pDCs heterogeneity, my technology can in fact be exploited to any cell type that shows heterogeneous function. My unique and high-risk technical approach allows for decoding immune cell-cell or cell-pathogen interactions longitudinally and in great detail which will revolutionise the fields of immunology and cellular immunotherapy. Ultimately, ImmunoCode will have a tremendous impact by refining the design of vaccine strategies and the development of differently composed cellular vaccines to battle cancer and infectious and auto-immune diseases.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores